Sign in

Private company

Aravive, Inc.

American pharmaceutical preparations company based in Houston2

In its 2023 annual report the company says: “We are a clinical-stage oncology company developing transformative treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Our current development program benefits from the availability of a proprietary serum-based biomarker that has accelerated batiraxcept drug development by allowing us to select a pharmacologically active dose and may potentially identify the cancer patients that have the best chance of responding to batiraxcept.”76

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersMenlo Park, United States2
  • Incorporated inTX3
  • Business addressRiver Oaks Tower, 3730 Kirby Drive, Suite 1200, Houston, Tx 770983
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493002Z0KHRW71RNC192
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Incorporating Services, Ltd., 19901 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 46321822

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-775.3%Operating margin4
-835.3%Net margin4
22.8%Revenue growth, 20224
-716.2%Return on equity4
-$65.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Other costs100¢$9.1M

Out of $9.1M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$9.1M in 2022−77% since 2017
0$10.0M$20.0M$30.0M$40.0M2017: $40.0M$40.0M20172018: $1.4M$1.4M2018−97%2019: $4.8M$4.8M2019+247%2020: $5.7M$5.7M2020+20%2021: $7.4M$7.4M2021+31%2022: $9.1M$9.1M2022+23%
Operating income956784-$70.8M in 2022−26% since 2016
-$100.0M-$75.0M-$50.0M-$25.0M02016: -$96.3M-$96.3M20162017: -$84.5M-$84.5M2017−12%2018: -$75.4M-$75.4M2018−11%2019: -$21.8M-$21.8M2019−71%2020: -$30.8M-$30.8M2020+41%2021: -$40.6M-$40.6M2021+32%2022: -$70.8M-$70.8M2022+74%
Net income956784-$76.3M in 2022−20% since 2016
-$100.0M-$75.0M-$50.0M-$25.0M02016: -$95.8M-$95.8M20162017: -$85.0M-$85.0M2017−11%2018: -$76.3M-$76.3M2018−10%2019: -$18.2M-$18.2M2019−76%2020: -$30.5M-$30.5M2020+68%2021: -$39.2M-$39.2M2021+28%2022: -$76.3M-$76.3M2022+95%
Fiscal year2016201720182019202020212022
Revenue$40.0M5$1.4M6$4.8M7$5.7M8$7.4M4$9.1M4
Research and development$72.0M9$94.6M5$11.1M5
Operating expenses$48.1M4$80.0M4
Operating income-$96.3M9-$84.5M5-$75.4M6-$21.8M7-$30.8M8-$40.6M4-$70.8M4
Interest$528.0K5$2.4M6
Income tax$247.0K9-$247.0K5$08$04$04
Net income-$95.8M9-$85.0M5-$76.3M6-$18.2M7-$30.5M8-$39.2M4-$76.3M4
Earnings per share-$1.954-$2.104
Shares (weighted, basic)20.1M shares436.4M shares4

Compare Aravive, Inc. with another company

Corporate structure

Aravive, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aravive, Inc.

  • Aravive, Inc. Menlo Park, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aravive, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.1M4 Dec 31, 2022$4.1M4 Dec 31, 2021+0.3%
Accumulated depreciation$2.8M4 Dec 31, 2022$2.7M4 Dec 31, 2021+5.2%
Property and equipment, net$270.0K4 Dec 31, 2022$400.0K4 Dec 31, 2021−32.5%
Operating-lease assets (leased space)$1.5M4 Dec 31, 2022$2.2M4 Dec 31, 2021−33.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$53.7M4 Dec 31, 2022$59.4M4 Dec 31, 2021−9.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, net$08 Dec 31, 2021$97.0K8 Dec 31, 2020−100.0%

Leadership

Who has led Aravive, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeffrey L. Cleland2014–2015
  2. Jay Shepard2015–2019
  3. Rekha Hemrajani2020
  4. Gail Frances McIntyre2020–2023

Chair

  1. Fredric N. Eshelman2022

President

  1. Jeffrey L. Cleland2014–2015
  2. Jay Shepard2015–2019
  3. Rekha Hemrajani2020
  4. Gail Frances McIntyre2020–2023

Chief financial officer

  1. Joshua T. Brumm2014–2017
  2. Vinay Shah2018–2022
  3. Rudy Howard2022–2023

Chief operating officer

  1. Joshua T. Brumm2017
  2. Leonard Scott Dove2022–2023
201520202025
Board members and other officers (31)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJohn A. Hohnecker named Oct 28, 202250
  • DirectorMichael W. Rogers named Oct 28, 202250

Former names

  • Versartis, Inc.Mar 9, 2011 to Oct 5, 20183

Timeline

  1. Jan 17, 20248-K Entered a material agreement; Completed an acquisition or sale; Listing notice or transfer51
  2. Nov 3, 20238-K Bylaws or fiscal year changed52
  3. Oct 3, 20238-K Shareholder vote53
  4. Sep 19, 20238-K Listing notice or transfer54
  5. Aug 2, 20238-K Results of operations; Regulation FD disclosure; Other events55
  6. Jun 5, 20238-K Regulation FD disclosure56
  7. May 25, 20238-K Regulation FD disclosure; Other events57
  8. May 16, 20238-K Regulation FD disclosure; Other events58
  9. May 10, 20238-K Results of operations59
  10. Apr 11, 20238-K Unregistered sale of shares; Executive or director change; Regulation FD disclosure60
  11. Mar 15, 20238-K Results of operations61
  12. Feb 28, 20238-K Regulation FD disclosure; Other events62
  13. Apr 9, 2020New chief executive Gail Frances McIntyre becomes CEO13
  14. Jan 9, 2020New chief executive Rekha Hemrajani becomes CEO12
  15. May 13, 2015New chief executive Jay Shepard becomes CEO14
  16. Mar 20, 2014New chief executive Jeffrey L. Cleland becomes CEO15
  17. Dec 10, 2008Founded Aravive, Inc. is founded2

Calendar

When it reported results

  1. Aug 2, 2023Reported quarterly or annual results55
  2. May 10, 2023Reported quarterly or annual results59
  3. Mar 15, 2023Reported quarterly or annual results61
  4. Nov 10, 2022Reported quarterly or annual results63
  5. Aug 11, 2022Reported quarterly or annual results64
  6. May 12, 2022Reported quarterly or annual results65
  7. Mar 31, 2022Reported quarterly or annual results66
  8. Oct 28, 2021Reported quarterly or annual results67

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

161 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 47 major events, 35 insider forms, 12 large holders, 1 private raises, 57 other. The latest 20:

  1. Feb 14, 2024SC 13G/A EDGAR
  2. Feb 14, 2024SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G EDGAR
  3. Feb 9, 2024SC 13G/A EDGAR
  4. Feb 8, 202415-12G EDGAR
  5. Feb 1, 2024EFFECT EDGAR
  6. Feb 1, 2024EFFECT EDGAR
  7. Feb 1, 2024EFFECT EDGAR
  8. Feb 1, 2024EFFECT EDGAR
  9. Feb 1, 2024EFFECT EDGAR
  10. Jan 29, 2024S-8 POS EDGAR
  11. Jan 29, 2024S-8 POS EDGAR
  12. Jan 29, 2024S-8 POS EDGAR
  13. Jan 29, 2024S-8 POS EDGAR
  14. Jan 29, 2024S-8 POS EDGAR
  15. Jan 29, 2024S-8 POS EDGAR
  16. Jan 29, 2024S-8 POS EDGAR
  17. Jan 29, 2024S-8 POS EDGAR
  18. Jan 29, 2024S-8 POS EDGAR
  19. Jan 29, 2024S-8 POS EDGAR
  20. Jan 29, 2024S-8 POS EDGAR

The 161 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 30, 2021Giaccia AmatoDirectorSale3,245$3.22$10.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$41.6M 2022–2022
Money received by yearMoney received by year, 2022–2022: $41.6M in all. Private raises (Form D) $41.6M.$0$20M$40M$60M2022 · Private raises (Form D): $41.6M2022
Figures by year
YearPrivate raises (Form D)Total
2022$41.6M$41.6M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 27, 2022Raised $41.6 million in a private offering of equity50 Form D: 17 investors so far Form D

SEC filer profile

How Aravive, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAravive, Inc.1
  • CIK0001513818
  • Employer ID (EIN)26-41066901
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inTexas1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressRiver Oaks Tower, 3730 Kirby Drive, Suite 1200, Houston, TX 770981
  • Phone936-355-19101
  • Shares outstanding73,562,648 as of Nov 3, 202311
  • Public float$19.1M as of Jun 30, 20224
  • On EDGAR sinceMar 9, 20111
  • Filings767 in all: 4 (272), 8-K (174), 3 (41), 10-Q (30), SC 13G/A (25), SC 13G (17), SC 13D/A (16), EFFECT (15)1
    All 44 form types

    CORRESP (12), UPLOAD (12), DEF 14A (11), S-8 (11), S-8 POS (11), 4/A (10), 10-K (9), 425 (9), CT ORDER (9), 424B5 (8), D (8), SC 13D (8), S-3 (7), S-1/A (6), POS AM (5), PRE 14A (5), 424B3 (4), 8-K/A (4), DEFA14A (3), S-3/A (3), 10-K/A (2), 424B4 (2), FWP (2), S-1 (2), S-4/A (2), SEC STAFF LETTER (2), 15-12G (1), 25 (1), 3/A (1), 8-A12B (1), ARS (1), CERTNAS (1), DEFR14A (1), DRS (1), NT 10-Q (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 15, 2023
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Sep 5, 2023
    Latest 8-K (8-K) Jan 17, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76